Form 4: ADC Therapeutics Director Robert Azelby Disposes of Shares for Tax Obligations

ADC Therapeutics SA Director Robert Azelby reported the disposition of 12,600 common shares at $3.58 per share to cover tax withholding obligations related to vested restricted share units.

Summary

• Robert Azelby, a Director of ADC Therapeutics SA (ADCT), reported a transaction on June 13, 2025.
• The transaction involved the disposition of 12,600 common shares.
• These shares were withheld by the Issuer (ADC Therapeutics SA) to satisfy Mr. Azelby's tax withholding obligations.
• The disposition was in connection with the vesting of previously granted restricted share units.
• The price per share for the disposition was $3.58.
• Following this transaction, Mr. Azelby beneficially owns 80,405 common shares directly.

Sentiment

Score: 5

Explanation: The document reports a routine insider transaction (shares withheld for tax) which is neutral in sentiment and an expected part of equity compensation plans. It does not indicate positive or negative operational or financial performance.

Future Outlook

This document does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically a share disposition to cover tax obligations. It does not provide broader insights into industry trends or competitive landscape, as it pertains to an individual's compensation-related share activity.

Stakeholder Impact

• Shareholders: This is a routine, non-discretionary transaction and is unlikely to have a significant impact on existing shareholders. It represents a small reduction in a director's direct holdings due to tax obligations.

Key Dates

Keywords

ADC Therapeutics, ADCT, Robert Azelby, Form 4, SEC filing, insider transaction, share disposition, tax withholding, restricted share units, corporate governance